Type to search

Epic Sciences Raises $43M in First Close of Series F Financing to Advance Comprehensive Profiling for Metastatic Cancer Patients | Pharmtech Focus
Epic Sciences and Biosplice Therapeutics Announce Partnership for Metastatic Cancer Trials | Pharmtech Focus